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Stent volume (mm3) 120± 31 120 ± 44 NS
Lumen volume Imm3) 36 ± 15 70 ± 26 <0.005
IH volume (mm3) 84± 30 50 ± 34 <0.05
In pts with focal in-stent restenosis, the region of greatest %AS was at the
central articulation in 9 (45%), at the stent margins in 6 (30%), and within a
stent segment in 5 (25%).
We Conclude: (1) IVUS imaging with automated transducer pullback al-
lows detailed volumetric analysis of in-stent restenosis. (2) In-stent resteno-
sis is due to a combination of reduced stent volume and greater IH. (3) Dif-
fuse in-stent restenosis is seen in less than 1/3 of restenotic stents and is
associated with more aggressive neointimal growth than the more common
pattern of focal restenosis. Further studies are required to determine if dif-
fering patterns of in-stent restenosis are associated with subsequent clinical
outcomes.
We then defined diffuse and focal patterns of restenosis: (1) diffuse =
more than 50% of the stent length having a %AS ::: 75 and (2) focal = less
than 50% of the stent length haVing a %AS ~ 75.
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Volumetric Intravascular Ultrasound Volumetric
Analysis Shows that Small Stent Size and Intimal
Hyperplasia Contribute to Restenosis
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F. Satler, Jeffrey J. Popma, Martin B. Leon. Washington Hospital Cente" Washington,
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To explore the mechanisms and patterns of stent restenosis, we performed
volumetric intravascular ultrasound analysis (IVUS) in 60 tubular-slotted
stents a mean of 8 months after implantation. Motorized transducer pull-
back (@ 0.5 mmls within a stationary imaging sheath) permitted measure-
ment of stent and lumen cross-sectional areas in 1 mm axial increments and
calculation of stent, lumen, and neointimal hyperplasia (IH = stent - lumen)
volumes using Simpson's Rule. Lumen areas were normalized for a refer-
ence lumen cross-sectional area to calculate a % area stenosis (AS) for each
cross-section. Restenosis was defined as a quantitative angiographic % di-
ameter stenosis ~ 50 or an IVUS %AS ~ 75.
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of Munich, Germany
A relational database was developed to enable relational analysis and cor-
relation of clinical data with morphologic changes of the arterial vessel
wall. A database system was designed which files all clinical, histological
and immunohistochemical data acquired by serial analysis of 177 primary
and restenotic tissue specimen obtained by directional atherectomy. The
database has been developed in a 4th Dimension (ACIUS, France) environ-
ment. Immunohistochemical analysis was performed of cellular and extra-
cellular components with 35 antibodies and the results were added to the
database to allow a relational analyzation of pathogenetic depencies. The
percentage of positive stained cells in 3 /lm thick serial cross-sections of
biopsies in a standardized manner (magnification x400, lOx 10 frames). All
values are given as percent of all present cells. Diabetic patients had a sig-
nificant increase of foam-cells (31 %) and collagen I (60%) compared with
all other patients (18%, 32%). Smoking and high cholesterol together led to
the highest incidence of restenosis (50%; total population: 27%) followed
by smoking alone (41 %) and was associated with enhanced cellular acti-
vation (i.e. high proliferation index and reduction of cytoskeletal filaments).
Restenosis had the lowest occurrence of foam-cells «5%) and a significant
reduction of contractile filaments (ct-SMC-actin: 65%, desmin: 14%) versus
85% and 54% in all biopsies. Restenosis, diabetes and smoking together
was associated with the highest occurrence of proliferation (restenoses 9%,
diabetes and smoking 6.1%).
Diabetes was associated with prolonged inflammation and enhanced ex-
tracellular matrix content. Determinants of clinical outcome after angioplasty
were high cholesterol levels, smoking and cellular activation in primary le-
sions. (Supported by a grant from Friedrich Baur Stiftung No. 58/94).
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Procedural Results and Long Term Clinical
Outcomes in Aorto-Ostial Saphenous Vein Graft
Lesions After New Device Angioplasty
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Kenneth M. Kent, Ya Chien Chuang, Theresa A. Bucher, Kathi Donovan, Martin
B. Leon. Washington Hospital Center, Washington, DC
Previously, we reported the high incidence of ischemic complications due to
distal embolization (DE) following extraction atherectomy (TEe) of degener-
ated saphenous vein grafts (DSVG: grafts with lumen ectasia or irregularities
comprising ~50% of the graft length), frequently caused by adjunct PTCA
(Group I). To assess whether a staged strategy (initial stand-alone TEC ± lyric
therapy, followed by coumadin and stenting 1-2 months later) could reduce
ischemic complications, we performed a pilot study in 28 pts with DSVG
(Group II). Demographics and graft age 1100 ± 47 vs. 99 ± 42 monthsl were
similar, except for more recent MI in Group II (58.3% vs. 22.7%, P = 0.03).
DS = diameter stenosis, *p < 0.001, **p = 0.20, and ***p = 0.15 vs. Group II
Preliminary Follow-up: Among 27 pts in Group II eligible for follow-up (> 1
month). there were no major ischemic complications. There were 4 total oc-
clusions [1 non-Q wave MI at 4 months and 3 silent occlusions at 6 weeks
(1) and 2 months (2)). 9 without clinical indication for additional therapy, 11
staged procedures with stenting (follow-up % DS = 56 ± 30%), and 3 with-
out significant stenosis on follow-up angiography. We conclude that this
staged angioplasty strategy in degenerated saphenous vein graft lesions:
1) may reduce distal embolization, but most importantly- avoids major in-
hospital ischemic complications during the initial procedure: but 2) at the
expense of "'15% graft occlusions, which occurred more than 6 weeks af-
ter the initial procedure: and 3) prevented any deaths either during the initial
procedure or during the follow-up period. These results underscore the im-
portance of early (1 month) follow-up in all patients undergoing this staged
TEC, followed by stent procedure in treating complex degenerated saphe-
nous vein graft lesions.
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Balloon angioplasty of aorto-ostial (AD, :0:3 mm from aorta) saphenous vein
graft (SVG) lesions has been associated with suboptimal results and high
restenosis frequency. New angioplasty devices are being utilized to treat AD-
SVG lesions but comparative efficacy has not been established. Therefore,
we compared the early procedural results and late clinical outcomes of 85
patients (90 lesions) treated with the Palmaz-Schatz stent IS) and 34 pts (41
lesions) treated with directional atherectomy (DCA). There was no difference
in pt demographics between the 2 groups. TLR = target lesion revascular-
ization, procedural success = final % stenosis >50% and no major compli-
cations (death, MI, CABG). and event free survival = freedom from major
complications or repeat PTCA at follow-up.
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Placement in Degenerated Saphenous Vein
Graft Lesions
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F. Saller, Ya Chien Chuang, Theresa Bucher, J. Hope Pacera, Martin B. Leon.
Washington Hospital Cente" Washington, DC
Angiographic Findings:
Ulceration (%)
Lesion lengthlAeference size (mm)
Acute gain (mm}/Final % stenosis
Clinical Findings:
Major complications (%)
Procedural success (%)
% TLR @ 6/12 months
% Event free survival 6/12 months
In conclusion: 1) Despite a higher frequency of adverse lesion characteris-
tics including ulceration and longer lesions, S placement aChieved improved
angiographic results (lower final % stenosis) compared to DCA. 21 Similarly,
late clinical outcomes favored S (vs DCA) with fewerTLR events and a higher
event free survival. 3) Nevertheless, the overall results of these new de-
vice modalities (S and DCA) for AO-SVG lesions are discouraging «50%
12-month event free survival) and mandate further therapy refinements to
improve late clinical outcomes.
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